Brief: Medincell Announces Product Portfolio And R&D Pipeline Progress
03/09/2024 16:54
Sept 3 (Reuters) - Medincell SA MEDCL.PA :
* MEDINCELL ANNOUNCES PROGRESS IN DEVELOPMENT OF ITS
PRODUCTS
PORTFOLIO AND RESEARCH AND DEVELOPMENT PIPELINE
* UZEDY® (RISPERIDONE LAI): REAFFIRMING REVENUE GUIDANCE FOR
2024
BY TEVA: C.$80 MILLION
* MEDINCELL MAY RECEIVE UP TO $105 MILLION IN COMMERCIAL
MILESTONES FOR UZEDY®
* COLLABORATION WITH ABBVIE: INITIATION OF PRECLINICAL AND
SUPPORTIVE CHEMISTRY, MANUFACTURING, AND CONTROLS WORK TO
ADVANCE LAI CANDIDATE INTO CLINICAL DEVELOPMENT
* COLLABORATION WITH ABBVIE: MEDINCELL ELIGIBLE TO RECEIVE
UP TO
$1.9 BILLION IN DEVELOPMENT AND COMMERCIAL MILESTONES
* COLLABORATION WITH ABBVIE: MEDINCELL IS ALSO ELIGIBLE TO
RECEIVE
MID-SINGLE TO LOW-DOUBLE-DIGIT ROYALTIES ON NET SALES
* OLANZAPINE LAI: FULL PHASE 3 SAFETY RESULTS ON TRACK FOR
H2 2024
Source text for Workspace: urn:newsml:reuters.com:*:nBw9lZ7qHa
Further company coverage: MEDCL.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))